Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

AMETEK INC/ (AME)

As of 2026-11-20 · 12/15 boxes filled from SEC filings and market data

Report price $222.90 (close 2026-11-20)

Conclusion: PASS

Conviction low · base case -3% · downside -26% · upside +20%

The market is paying for a post-deal AMETEK at 31.3x TTM earnings and 22.3x EV/EBITDA, while the reverse DCF requires +7.0% revenue growth a year for 10 years against +6.6% in FY2025. The record operating performance is visible, but the price already discounts steady delivery, so the balanced setup supports the call. The downside case is -26.3% to $164.21, from -10.0% earnings at a compressed P/E of 25.65x (today 31.3x). The base case is -3.2% to $215.78, from P/E at 30.3x, the peer median P/E. The upside case is +20.1% to $267.70, from +20.1% earnings at today's P/E of 31.3x. The range is wide enough to keep conviction low: the base offers little cushion, the downside is a real earnings-compression outcome, and the upside needs the current multiple to hold on higher earnings. With delivery and Indicor integration as the proof points, PASS is the call.

Key numbers

  • Share price: $222.90
  • Market cap: $51.11B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $8.19B
  • EV / EBITDA (TTM): 22.3x
  • P/E (TTM): 31.3x
  • FCF yield: 3.8%
  • Price / book: 4.37x
  • EV / FCF (TTM): 29.6x
  • Revenue growth (latest fiscal year): +6.6%
  • ROIC (TTM): 9.8%
  • WACC: 7.8%
  • Economic profit spread: +2.0 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    AMETEK, whose predecessor was incorporated in 1930 as American Machine and Metals, makes money through two niche manufacturing groups: EIG (advanced analytical, test and measurement instruments; 70% process/analytical and 30% aerospace/power of EIG FY2025 net sales) and EMG (precision motion control, medical components/devices, thermal management, specialty metals and interconnects; 70% automation/engineered and 30% aerospace of EMG FY2025 net sales). FY2025 sales were $7,401.1M, up 6.6%, with operating income $1.91B and net income $1.48B; TTM to 2026-09-30 revenue was $8.19B and operating income $2.13B. Between the FY2020 and FY2025 reports the company used acquisitions (15 deals since 2021, ~$1.8B annualized sales) and shifted its Growth Model target to high single digit sales growth, while EIG's process/analytical mix fell to 70% from 73% and EMG's description added medical components/devices.

  2. ✓ 2. Competitive advantage

    AMETEK's advantage is visible mainly in the numbers, not in the language: operating margin held at roughly 24-26% of revenue across FY2022-FY2025 and the TTM to 2026-09-30 (about 26.0% TTM), with capex only about 1.8% of revenue and operating cash flow about 1.28x net income in the TTM. The 10-K describes the markets as "highly competitive" on technology, performance, quality, service and price, with "numerous companies" competing in each process and analytical instrument market, no single patent or trademark deemed essential, and no competitors named or market shares quantified. Returns on book equity are only about 14% (TTM net income $1.63B over $11.70B equity), and the 10-K itself flags cyclical served markets and rivals with greater resources, so the record reads as a strong-margin niche franchise rather than a moat the filings document.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 was a record quarter: sales $2.22B (+17% y/y), GAAP operating income $584.9M and GAAP diluted EPS $1.85, with adjusted EPS $2.21 (+17%) after adding back $0.36 of acquisition amortization and deal costs. Adjusted operating margin rose 60bp to 26.8% and core margins expanded 110bp, while quarter operating cash flow grew 27% to $560.6M at 124% free-cash-flow conversion. The company raised FY2026 adjusted EPS guidance to $8.53-$8.57 from $8.20-$8.30 on mid-teens sales growth, and guided Q4 adjusted EPS to $2.26-$2.30. The quarter's balance sheet is transformed by $5,345.8M of acquisition cash paid (Indicor in August 2026), funded with $4.0B of term loans, and buybacks fell to near zero versus $150.5M in Q3 2025.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans